Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance. / Schmidt, Nina; Møller, Grith; Bæksgaard, Lene; Østerlind, Kell; Stark, Ken D; Lauritzen, Lotte; Andersen, Jens Rikardt.

I: Clinical Nutrition ESPEN, Bind 35, 2020, s. 63-68.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Schmidt, N, Møller, G, Bæksgaard, L, Østerlind, K, Stark, KD, Lauritzen, L & Andersen, JR 2020, 'Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance', Clinical Nutrition ESPEN, bind 35, s. 63-68. https://doi.org/10.1016/j.clnesp.2019.12.004

APA

Schmidt, N., Møller, G., Bæksgaard, L., Østerlind, K., Stark, K. D., Lauritzen, L., & Andersen, J. R. (2020). Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance. Clinical Nutrition ESPEN, 35, 63-68. https://doi.org/10.1016/j.clnesp.2019.12.004

Vancouver

Schmidt N, Møller G, Bæksgaard L, Østerlind K, Stark KD, Lauritzen L o.a. Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance. Clinical Nutrition ESPEN. 2020;35:63-68. https://doi.org/10.1016/j.clnesp.2019.12.004

Author

Schmidt, Nina ; Møller, Grith ; Bæksgaard, Lene ; Østerlind, Kell ; Stark, Ken D ; Lauritzen, Lotte ; Andersen, Jens Rikardt. / Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance. I: Clinical Nutrition ESPEN. 2020 ; Bind 35. s. 63-68.

Bibtex

@article{34ed8a62aac0438c90cc490338eb6877,
title = "Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance",
abstract = "Background & aims: Fish-oil, rich in Omega-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs), may in high doses inhibit the development or progression of cancer cachexia. However, poor compliance to oral nutritional supplements is a well-known problem. We aimed to investigate acceptability and compliance to a nutritional drink with fish-oil compared to an equivalent dose of fish-oil administered as capsules in patients receiving chemotherapy for GI tract cancers. Moreover, we aimed to investigate, if there was a difference between a nutritional drink or capsules with respect to nutritional status and side effects. Finally, we aimed to examine, if n-3 LC PUFAs affect leukocyte and platelet counts, and markers of dose-limiting toxicities of chemotherapy.Methods: We consecutively included 41 patients with advanced cancer in the controlled study. Patients were allocated (not randomized) to ingest either 10 capsules/day for four weeks or 400 mL/day of a nutritional drink with same dose of n-3 LC PUFA dose. Compliance was assessed by daily self-registration and n-3 LC PUFAs in whole blood. Side effects were assessed by 10 cm visual analog scales.Results: Compliance and daily consumption of n-3 LC PUFAs were 96.4{\%} (94.1e99.3) and 4.8 (4.7e4.9) g/day in the capsule group and 80.8 (55.4e93.6) {\%} and 4.0 (2.8e4.7) g/day in the group, respectively (p 0.02). We found no differences between the groups with respect to changes in whole blood n-3 LCPUFAs, weight, nutritional status, acceptability or side effects. However, in the capsule group the whole blood n-3 LC PUFAs correlated negatively with the increase in nausea (rs ¼ 0.39, p ¼ 0.05), but not in the nutritional drink group. Nausea, reduced appetite and loose stools were of greatest importance for the deviations from recommended doses. The number of capsules had a negative impact on acceptability and compliance, whereas this was mainly related to taste and texture in the nutritional drink group. No changes in median thrombocyte or leukocyte blood counts were observed.Conclusions: Fish oil in capsules appeared to result in better compliance compared to a nutritional drink with an equivalent dose of n-3 LC PUFAs. However, capsules and the drink did not differ with respect to the effect on nutritional status or side effects.Trial registration ClinicalTrials.gov Identifier: NCT03751384.",
keywords = "Faculty of Science, n-3 LC PUFA, EPA, Cancer cachexia, Chemotherapy, Product acceptability",
author = "Nina Schmidt and Grith M{\o}ller and Lene B{\ae}ksgaard and Kell {\O}sterlind and Stark, {Ken D} and Lotte Lauritzen and Andersen, {Jens Rikardt}",
note = "CURIS 2020 NEXS 006",
year = "2020",
doi = "10.1016/j.clnesp.2019.12.004",
language = "English",
volume = "35",
pages = "63--68",
journal = "Clinical Nutrition ESPEN",
issn = "2405-4577",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance

AU - Schmidt, Nina

AU - Møller, Grith

AU - Bæksgaard, Lene

AU - Østerlind, Kell

AU - Stark, Ken D

AU - Lauritzen, Lotte

AU - Andersen, Jens Rikardt

N1 - CURIS 2020 NEXS 006

PY - 2020

Y1 - 2020

N2 - Background & aims: Fish-oil, rich in Omega-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs), may in high doses inhibit the development or progression of cancer cachexia. However, poor compliance to oral nutritional supplements is a well-known problem. We aimed to investigate acceptability and compliance to a nutritional drink with fish-oil compared to an equivalent dose of fish-oil administered as capsules in patients receiving chemotherapy for GI tract cancers. Moreover, we aimed to investigate, if there was a difference between a nutritional drink or capsules with respect to nutritional status and side effects. Finally, we aimed to examine, if n-3 LC PUFAs affect leukocyte and platelet counts, and markers of dose-limiting toxicities of chemotherapy.Methods: We consecutively included 41 patients with advanced cancer in the controlled study. Patients were allocated (not randomized) to ingest either 10 capsules/day for four weeks or 400 mL/day of a nutritional drink with same dose of n-3 LC PUFA dose. Compliance was assessed by daily self-registration and n-3 LC PUFAs in whole blood. Side effects were assessed by 10 cm visual analog scales.Results: Compliance and daily consumption of n-3 LC PUFAs were 96.4% (94.1e99.3) and 4.8 (4.7e4.9) g/day in the capsule group and 80.8 (55.4e93.6) % and 4.0 (2.8e4.7) g/day in the group, respectively (p 0.02). We found no differences between the groups with respect to changes in whole blood n-3 LCPUFAs, weight, nutritional status, acceptability or side effects. However, in the capsule group the whole blood n-3 LC PUFAs correlated negatively with the increase in nausea (rs ¼ 0.39, p ¼ 0.05), but not in the nutritional drink group. Nausea, reduced appetite and loose stools were of greatest importance for the deviations from recommended doses. The number of capsules had a negative impact on acceptability and compliance, whereas this was mainly related to taste and texture in the nutritional drink group. No changes in median thrombocyte or leukocyte blood counts were observed.Conclusions: Fish oil in capsules appeared to result in better compliance compared to a nutritional drink with an equivalent dose of n-3 LC PUFAs. However, capsules and the drink did not differ with respect to the effect on nutritional status or side effects.Trial registration ClinicalTrials.gov Identifier: NCT03751384.

AB - Background & aims: Fish-oil, rich in Omega-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs), may in high doses inhibit the development or progression of cancer cachexia. However, poor compliance to oral nutritional supplements is a well-known problem. We aimed to investigate acceptability and compliance to a nutritional drink with fish-oil compared to an equivalent dose of fish-oil administered as capsules in patients receiving chemotherapy for GI tract cancers. Moreover, we aimed to investigate, if there was a difference between a nutritional drink or capsules with respect to nutritional status and side effects. Finally, we aimed to examine, if n-3 LC PUFAs affect leukocyte and platelet counts, and markers of dose-limiting toxicities of chemotherapy.Methods: We consecutively included 41 patients with advanced cancer in the controlled study. Patients were allocated (not randomized) to ingest either 10 capsules/day for four weeks or 400 mL/day of a nutritional drink with same dose of n-3 LC PUFA dose. Compliance was assessed by daily self-registration and n-3 LC PUFAs in whole blood. Side effects were assessed by 10 cm visual analog scales.Results: Compliance and daily consumption of n-3 LC PUFAs were 96.4% (94.1e99.3) and 4.8 (4.7e4.9) g/day in the capsule group and 80.8 (55.4e93.6) % and 4.0 (2.8e4.7) g/day in the group, respectively (p 0.02). We found no differences between the groups with respect to changes in whole blood n-3 LCPUFAs, weight, nutritional status, acceptability or side effects. However, in the capsule group the whole blood n-3 LC PUFAs correlated negatively with the increase in nausea (rs ¼ 0.39, p ¼ 0.05), but not in the nutritional drink group. Nausea, reduced appetite and loose stools were of greatest importance for the deviations from recommended doses. The number of capsules had a negative impact on acceptability and compliance, whereas this was mainly related to taste and texture in the nutritional drink group. No changes in median thrombocyte or leukocyte blood counts were observed.Conclusions: Fish oil in capsules appeared to result in better compliance compared to a nutritional drink with an equivalent dose of n-3 LC PUFAs. However, capsules and the drink did not differ with respect to the effect on nutritional status or side effects.Trial registration ClinicalTrials.gov Identifier: NCT03751384.

KW - Faculty of Science

KW - n-3 LC PUFA

KW - EPA

KW - Cancer cachexia

KW - Chemotherapy

KW - Product acceptability

U2 - 10.1016/j.clnesp.2019.12.004

DO - 10.1016/j.clnesp.2019.12.004

M3 - Journal article

C2 - 31987122

VL - 35

SP - 63

EP - 68

JO - Clinical Nutrition ESPEN

JF - Clinical Nutrition ESPEN

SN - 2405-4577

ER -

ID: 233583111